Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® (Dry AMD)
    • OPC1 (Spinal Cord Injury)
    • VAC2 (Immuno-oncology)
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Charters and Documents
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Report and Proxy Information
      • 2018 AgeX Form 10 and Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu Menu
IR MinutesKOL VideosInterviews
PreviousNext

A regularly updated video series answering a selection of frequently asked investor questions

January 27, 2020

Dry AMD Competitive Landscape Overview & OpRegen Positioning

January 9, 2020

VAC2 Program & Research Partnership with CRUK

December 31, 2019

Review of cost efficient business model & plans for 2020

December 17, 2019

Review of recent results from OpRegen Phase I/IIa study

Key opinion leaders discuss topics related to Lineage’s clinical programs

Why is dry age-related macular degeneration (dry AMD) research so important?

Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research

Why is spinal cord research so important?

Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC

Videos and interviews from specific events, conferences, or showcases

Solebury Trout Talks

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX)
NameTag Series – Feb. 7th, 2020

Lineage Cell CEO encouraged about its dry AMD data

CEO Brian Culley chats with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco

H.C.Wainwright & Co. Annual Global Investment Conference

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX)
Investor Presentation Sep 18th 2019
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   [email protected]
  • Facebook
  • Twitter
  • LinkedIn
Scroll to top